Related Experiment Video
Updated: Dec 26, 2025
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus
Arun Kapoor1, Ayan K Ghosh1, Michael Forman2
1Department of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States.
Abstract:
The critical consequences of human cytomegalovirus (HCMV) infection in the transplant population and in congenitally infected infants, the limited treatment options for HCMV, and the rise of resistant mutants toward existing therapies has fueled the search for new anti-HCMV agents. A pp28-luciferase recombinant HCMV was used as a reporter system for high-throughput screening of HCMV inhibitors. Approximately 400 000 compounds from existing libraries were screened. Subsequent validation assays using resynthesized compounds, several virus strains, and detailed virology assays resulted in the identification of five structurally unique and selective HCMV inhibitors, active at sub to low micromolar concentrations. Further characterization revealed that each compound inhibited a specific stage of HCMV replication. One compound was also active against herpes simplex virus (HSV1 and HSV2), and another compound was active against Epstein-Barr virus (EBV). Drug combination studies revealed that all five compounds were additive with ganciclovir or letermovir. Future studies will focus on optimization of these new anti-HCMV compounds along with mechanistic studies.
Insights
Researchers screened 400,000 compounds to find new human cytomegalovirus (HCMV) treatments. Five unique inhibitors were identified, targeting specific replication stages and showing promise against resistant strains.
Area of Science:
- Virology
- Drug Discovery
- Antiviral Research
Background:
- Human cytomegalovirus (HCMV) poses significant risks to transplant recipients and congenitally infected infants.
- Limited treatment options and emerging drug resistance necessitate novel anti-HCMV agents.
Purpose of the Study:
- To identify novel, selective inhibitors of human cytomegalovirus (HCMV).
- To discover compounds effective against drug-resistant HCMV strains.
Main Methods:
- High-throughput screening of approximately 400,000 compounds using a pp28-luciferase reporter system.
- Validation of hits through resynthesis, diverse virus strains, and detailed virology assays.
- Evaluation of drug combinations with existing antivirals like ganciclovir and letermovir.
Main Results:
- Identification of five structurally unique HCMV inhibitors with sub- to low-micromolar activity.
- Each compound demonstrated specific inhibition of distinct HCMV replication stages.
- Broadened antiviral activity observed for two compounds against HSV and EBV.
- All identified compounds showed additive effects when combined with ganciclovir or letermovir.
Conclusions:
- Discovery of five novel HCMV inhibitors offers potential new therapeutic avenues.
- Compounds target specific viral replication steps, suggesting diverse mechanisms of action.
- Further optimization and mechanistic studies are warranted for clinical development.
